GSK Raises Prospects For Withdrawn Blood Cancer Drug Blenrep …
8 hours ago · On Thursday, GSK plc (NYSE:GSK) released headline results from a planned interim analysis of the DREAMM-7 head-to-head phase 3 trial of Blenrep (belantamab mafodotin) in combination with ...
GSK’s Withdrawn Blood Cancer Drug Paves Path Back to Market
20 hours ago · GSK’s Withdrawn Blood Cancer Drug Paves Path Back to Market. Signage at a GlaxoSmithKline facility in Rockville, Maryland, US, on Monday, Aug. 26, 2024. The US Food and Drug Administration has granted Breakthrough Therapy Designation for GSK227, an investigational B7-H3-targeted antibody drug conjugate being evaluated for the treatment of ...
GSK's ADC Blenrep delivers survival win against J&J's Darzalex
14 hours ago · In boost to GSK's £3B plan for Blenrep, myeloma ADC shows survival edge over J&J's Darzalex. GSK’s 3 billion pounds sterling peak sales goal for its multiple myeloma drug Blenrep appears ...
Blenrep shows overall survival benefit in head-to-head DREAMM-7 ... - GSK
1 day ago · Hesham Abdullah, Senior Vice President, Global Head Oncology, R&D, GSK, said: “The overall survival results from the DREAMM-7 trial underscore the potential for this Blenrep combination to extend the lives of patients with relapsed/refractory multiple myeloma. This is a statistically significant and clinically meaningful advancement for ...
GSK Steps Up Parkinson’s Focus With US Biotech Deal
2 days ago · Listen. 1:49. GSK Plc agreed on a partnership deal worth as much as $650 million with US biotech Vesalius Therapeutics to help advance drug development for Parkinson’s disease. GSK will pay $80 ...
GSK pays Flagship biotech $80M for preclinical neuro pact
2 days ago · GSK inks Parkinson's pact with Flagship's Vesalius for $570M-plus biobucks. GSK is paying $80 million to ink a multi-target neurodegenerative pact with Flagship-founded Vesalius Therapeutics that ...
Press release archive - GSK
Browse GSK's global press release archive for media and investors. Search by keyword or browse by year/business category. Press releases issued by our local operating companies can be viewed on our market websites.
Health Canada approves GSK’s Ojjaara for ... - Yahoo Finance
1 day ago · GSK. Health Canada has granted approval for GlaxoSmithKline’s (GSK) Ojjaara (momelotinib) for treating myelofibrosis (MF) in adults with moderate-to-severe anaemia. The once-daily, oral ...
GSK invests up to $800 million in Pennsylvania site, largest ...
Oct 24, 2024 · The up to $800 million investment will bring state-of-the-art drug substance manufacturing and additional drug product manufacturing capabilities to the company’s site in Marietta, Pennsylvania, along with over 200 new jobs.
GSK partners with Flagship startup to hunt for Parkinson’s drugs
3 days ago · The deal with GSK represents an upturn in fortune for Vesalius, which laid off 40% of its workforce in September 2022. Launched in 2019, the startup was co-founded by Christopher Austin, the former director of the National Institutes of Health’s National Center for Advancing Translational Sciences, and Doug Cole, a managing partner at Flagship. ...
- Some results have been removed